Pliant Therapeutics, Inc. (PLRX) company profile

Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing integrin-based therapeutics for the treatment of solid tumors and other diseases. The company utilizes a proprietary drug discovery platform built around a library of over 15,000 integrin-binding molecules to generate targeted treatments and cell-specific drug delivery mechanisms. Its lead wholly owned product candidate, PLN-101095, is an oral, small molecule dual inhibitor targeting αvβ8 and αvβ1 integrins designed to sensitize tumors to immunotherapies. Pliant evaluates its therapies for patients with cancers resistant to immune checkpoint inhibitors.

The company operates without internal manufacturing facilities, outsourcing all clinical drug substance production, formulation, testing, and storage to third-party contract manufacturers, including suppliers in Asia. Pliant holds intellectual property portfolios comprising domestic and international patents across North America and foreign jurisdictions. The provided text details clinical operations and global patent protections, but it does not disclose a specific headquarters location or explicit facility count.

Summary of the business section of Pliant Therapeutics's latest annual report, written by StockData.

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

“The initial public offering price is $16.00 per share of common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

“As of December 31, 2025, we had 49 full-time employees, including 19 with Ph.D.”